[1] WHO. Global hepatitis report 2017. Geneva. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (Accessed April 4, 2019). [2] Liu J, Wang L, Jing W, et al. Coutdown to 2030: eliminating hepatitis Bdisease, China. Bull World Health Organ,2019,97(3):230-238. [3] Chen J,Wang ML,Long Q,et al.High value of controlled at-tenuation parameter predicts a poor antiviral response in patients with chronic hepatits B. Hepatobiliary Pancreat Dis Int,2017,16(4):370-374. [4] Terrault NA, Lok AS, Mcmahon BJ,et al.Update on prevention,diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance.Hepatology,2018,67(4):1560-1599. [5] Tang LSY,Covert E,Wilson E,et al.Chronic hepatitis B infection:A review.JAMA,2018,319(17):1802-1813. [6] Lieveld FI,van Vlerken LG,Siersema PD,et al.Patient adherence to antiviral treatment for chronic hepatitis B and C:a systematic review.Ann Hepatol,2013,12(3):380-391. [7] Baig M,Tariq S,Rehman R,et al.Concept mapping improves academic performance in problem solving questions in biochemistry subject.Pak J Med Sci,2016,32(4):801-805. [8] Ying G,Jianping X,Haiyun L,et al. Using mind maps to improve medical student performance in a pharmacology course at Kunming medical university.J Coll Physicians Surg Pak,2017,27(7):404-408. [9] 邓莹,潘卫宇,左珊珊,等.思维导图在一期翻修术治疗全膝关节置换术后感染患者围手术期的应用.中华医院感染学杂志,2017,27(19):4480-4483. [10] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ. [11] Yamashita M. The exercise of self-care agency scale. West J Nurs Res,1998,20(3):370-381. [12] Morisky DE,Ang A,Krousel-Wood M,et al.Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich),2008,10(5):348-354. [13] 江学成,晓兵,王增慧,等.利用思维导图编写临床教案探讨.中华医学教育探索杂志,2013,12(11):1151-1154. [14] Booker SQ,Peterson N.Use of the knowledge tree as a mind map in a gerontologic course for undergraduate nursing student.J Nurs Educ,2016,55(3):182-184. [15] Hsu CW, Su WW,Lee CM,et al. Phase Ⅳ randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc, 2018. 117(7):588-597. [16] 安宝燕,王云,项晓刚,等.乙型肝炎相关性肝细胞癌患者预后在多因素分析.实用肝脏病杂志,2018,21(6):924-927. [17] Mak LY,Seto WK,Fung J,et al.Novel developments of hepatitis B:treatment goals,agents and monitoring tools. Expet Rev Clin Pharmacol,2019,12(2):109-120. [18] Xu Y,Zhang YG,Wang Y, et al.Long-term antival efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.World J Gastroenterol,2015,21(25):7869-7876. [19] Ashur ST, Shamsuddin K, Shah SA, et al.Reliabbility and know-group validity of the Arabic version of the 8-item Morisky Medication Adherence Scale among type 2 diabetes mellitus patients. East Mediterr Health J,2015,21(10):722-728. [20] Moharamzad Y,Saadat H, Nakhjavan Shahraki B,et al.Validation of the Persian version of the 8-item Morisky Medication Adherence Scale(MMAS-8) in Iranian hepertensive patients.Glob J Health Sci,2015,7(4):173-183. [21] 于爱东,王传杰,李建芳.群组管理模式对提高慢性乙型肝炎患者抗病毒治疗依从性的作用研究.实用肝脏病杂志,2018,21(4):621-622. |